HomeIsraelAION Labs Partners With Amiti Ventures

AION Labs Partners With Amiti Ventures

AION Labs, a Rehovot, Israel-based venture studio focused on the adoption of AI technologies and computational science to solve therapeutic challenges, announced a new strategic partnership with Amiti Ventures, an early-stage venture capital firm.

The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups.

The partnership with Amiti Ventures will help AION Labs to advance healthcare towards patient-centric precision medicine. Amiti’s experience and track record in these fields will bring investor knowledge and insights to AION Labs, enabling it to more effectively develop and support early-stage startups focused on AI and computational biology. Its first investment in the venture studio will entail investment in DenovAI Biotech’s Seed round of funding. Launched in 2022, DenovAI is developing an AI-powered biophysics solution for de novo antibody and protein design.

Led by Mati Gill, CEO, AION Labs is an alliance of Astrazeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and Amazon Web Services (AWS), powered by BioMed X with the support of the Israeli Government via the Israel Innovation Authority, to create and adopt new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.

The lab builds and invests in early-stage startup teams focused on AI and computational biology in drug discovery and development, offering them resources and mentorship while working closely with them to develop new technologies that meet the most significant challenges in the pharmaceutical industry.

Led by Ben Rabinowitz, Founder and Managing Partner, Amiti Ventures is a deep tech venture capital firm focused on finding seed stage outlier companies developing transformational technologies. The firm targets quantum computing and computational and synthetic biology, where Israelhas some of the most promising founders, expertise and multi-disciplinary skills in the world.